Portside Wealth Group LLC Reduces Stake in Zoetis Inc. $ZTS

Portside Wealth Group LLC trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 20.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 24,315 shares of the company’s stock after selling 6,091 shares during the quarter. Portside Wealth Group LLC’s holdings in Zoetis were worth $3,059,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. CIBC Asset Management Inc lifted its stake in shares of Zoetis by 4.3% during the 3rd quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after buying an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp lifted its stake in shares of Zoetis by 6.5% during the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after buying an additional 18,040 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Zoetis by 79.2% during the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Ninety One UK Ltd lifted its stake in shares of Zoetis by 19.6% during the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock valued at $163,751,000 after buying an additional 183,686 shares in the last quarter. Finally, Quilter Plc lifted its stake in shares of Zoetis by 10.2% during the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock valued at $64,228,000 after buying an additional 40,615 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ZTS. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, March 27th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Barclays began coverage on Zoetis in a research note on Monday, December 8th. They issued an “equal weight” rating and a $136.00 target price for the company. Bank of America raised their target price on Zoetis from $135.00 to $140.00 and gave the stock a “neutral” rating in a research note on Friday, February 13th. Finally, Leerink Partners restated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Zoetis presently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Stock Performance

NYSE ZTS opened at $118.17 on Tuesday. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The stock has a market capitalization of $49.88 billion, a PE ratio of 19.63, a P/E/G ratio of 1.80 and a beta of 0.98. The company’s 50 day simple moving average is $122.60 and its two-hundred day simple moving average is $127.75.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same period in the prior year, the company posted $1.40 EPS. The business’s revenue for the quarter was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.